Related Experiment Video

Updated: May 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling

S Kasper1, F Breitenbuecher, H Reis

  • 1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Oncogene
|July 17, 2012
PubMed

Insights

RAS mutations in cancer confer resistance to epidermal growth factor receptor (EGFR) antibody therapies by upregulating BCL-XL. Targeting BCL-XL can restore sensitivity to these vital cancer treatments.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are established cancer therapies.
  • Tumors with RAS mutations exhibit resistance to anti-EGFR antibodies, limiting their clinical efficacy.

Purpose of the Study:

  • To investigate the mechanisms of RAS-mediated resistance to clinically approved anti-EGFR antibodies, cetuximab and panitumumab.
  • To explore strategies for overcoming this resistance.

Main Methods:

  • Comparative analysis of cetuximab and panitumumab in cancer models.
  • In vitro cytotoxicity assays and in vivo efficacy studies.
  • Investigation of BCL-XL upregulation in response to RAS mutations and its role in resistance.

Main Results:

  • Both antibodies showed equal in vitro cytotoxicity, but cetuximab demonstrated superior in vivo efficacy due to antibody-dependent cellular cytotoxicity (ADCC).
  • Oncogenic RAS neutralized the in vivo activity of both antibodies by upregulating BCL-XL.
  • Suppression of BCL-XL restored sensitivity to anti-EGFR antibodies in RAS-mutant models.

Conclusions:

  • RAS-mutant tumors evade anti-EGFR antibody therapy through both receptor blockade and ADCC resistance.
  • Targeting RAS signaling pathways, specifically BCL-XL, can re-sensitize tumors to antibody-based treatments.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: